OBJECTIVE: To assess the effect of HIV coreceptor tropism (CRT) on the relative risk of progression to a composite outcome of CD4 count < or =350 cells per microliter, treatment initiation, or death. METHODS: CRT assays were performed after study closure in baseline samples obtained from enrollees in a prospectively monitored cohort of treatment-naive adults with > or =450 CD4 cells per microliter and > or =1000 HIV-1 RNA copies per milliliter. RESULTS: Dual/mixed (D/M) and R5 CRT were detected in 32 and 282 patients, respectively. The baseline CD4 count (617 versus 694 cells/microL; P = 0.05) differed in patients with D/M versus R5 CRT. Otherwise, baseline laboratory characteristics were similar.The relative risk of progression to the composite end point was 2.15 (P = 0.002) for D/M versus R5 CRT, 2.07 per 1.0 log10 higher viral load (P < 0.001) and 0.87 per 50 cells per microliter higher CD4 cell count (P < 0.001). The effect of D/M CRT was also significant in separate analyses of time to initiation of antiretroviral therapy or CD4 cell count < or =350 cells per microliter. CONCLUSIONS: Untreated patients with D/M rather than R5 CRT had a faster rate of disease progression, whether assessed by a composite outcome of time to CD4 count < or =350 cells per microliter, treatment initiation, or death or by separate analyses of time to CD4 count < or =350 cells per microliter or treatment initiation.
OBJECTIVE: To assess the effect of HIV coreceptor tropism (CRT) on the relative risk of progression to a composite outcome of CD4 count < or =350 cells per microliter, treatment initiation, or death. METHODS:CRT assays were performed after study closure in baseline samples obtained from enrollees in a prospectively monitored cohort of treatment-naive adults with > or =450 CD4 cells per microliter and > or =1000 HIV-1 RNA copies per milliliter. RESULTS: Dual/mixed (D/M) and R5 CRT were detected in 32 and 282 patients, respectively. The baseline CD4 count (617 versus 694 cells/microL; P = 0.05) differed in patients with D/M versus R5 CRT. Otherwise, baseline laboratory characteristics were similar.The relative risk of progression to the composite end point was 2.15 (P = 0.002) for D/M versus R5 CRT, 2.07 per 1.0 log10 higher viral load (P < 0.001) and 0.87 per 50 cells per microliter higher CD4 cell count (P < 0.001). The effect of D/M CRT was also significant in separate analyses of time to initiation of antiretroviral therapy or CD4 cell count < or =350 cells per microliter. CONCLUSIONS: Untreated patients with D/M rather than R5 CRT had a faster rate of disease progression, whether assessed by a composite outcome of time to CD4 count < or =350 cells per microliter, treatment initiation, or death or by separate analyses of time to CD4 count < or =350 cells per microliter or treatment initiation.
Authors: E A Berger; R W Doms; E M Fenyö; B T Korber; D R Littman; J P Moore; Q J Sattentau; H Schuitemaker; J Sodroski; R A Weiss Journal: Nature Date: 1998-01-15 Impact factor: 49.962
Authors: M D Hughes; V A Johnson; M S Hirsch; J W Bremer; T Elbeik; A Erice; D R Kuritzkes; W A Scott; S A Spector; N Basgoz; M A Fischl; R T D'Aquila Journal: Ann Intern Med Date: 1997-06-15 Impact factor: 25.391
Authors: J C Learmont; A F Geczy; J Mills; L J Ashton; C H Raynes-Greenow; R J Garsia; W B Dyer; L McIntyre; R B Oelrichs; D I Rhodes; N J Deacon; J S Sullivan Journal: N Engl J Med Date: 1999-06-03 Impact factor: 91.245
Authors: K Grovit-Ferbas; J Ferbas; V Gudeman; S Sadeghi; M B Goetz; J V Giorgi; I S Chen; W A O'Brien Journal: J Virol Date: 1998-11 Impact factor: 5.103
Authors: Andrew D Redd; Oliver Laeyendecker; Xiangrong Kong; Noah Kiwanuka; Tom Lutalo; Wei Huang; Ronald H Gray; Maria J Wawer; David Serwadda; Susan H Eshleman; Thomas C Quinn Journal: AIDS Res Hum Retroviruses Date: 2011-08-05 Impact factor: 2.205
Authors: Julia G Prado; Andrew Prendergast; Christina Thobakgale; Claudia Molina; Gareth Tudor-Williams; Thumbi Ndung'u; Bruce D Walker; Philip Goulder Journal: J Virol Date: 2010-01 Impact factor: 5.103
Authors: Matthew Bidwell Goetz; Robert Leduc; Nicole Wyman; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk Journal: J Acquir Immune Defic Syndr Date: 2010-04-01 Impact factor: 3.731